<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  Advise patients:<BR>                  <BR>                     <BR>                        •To take premedications, including thyroid-blocking agents as prescribed [see Warnings and Precautions (5.5)]. <BR>                     <BR>                        •To contact a healthcare professional if they experience signs and symptoms of allergic reactions [see Warnings and Precautions (5.1)].<BR>                     <BR>                     <BR>                        •To report to a health care professional any signs of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue, or symptoms of infection such as fever) [see Warnings and Precautions (5.2)]. <BR>                     <BR>                        •Of the need for frequent monitoring for up to 3 months after treatment, and the potential for persistent cytopenias beyond 3 months. <BR>                     <BR>                        •Concerning the risk of radiation exposure to household contacts, pregnant women and small children from radioactive materials remaining in the patient’s body following the BEXXAR therapeutic regimen. Provide patient-specific advice orally and in writing [see Warnings and Precautions (5.3)]. <BR>                     <BR>                        •Of the need for life-long monitoring for hypothyroidism [see Warnings and Precautions (5.5)]. <BR>                     <BR>                        •Who are pregnant that the BEXXAR therapeutic regimen can cause hypothyroidism in the infant [see Warnings and Precautions (5.6), Use in Special Populations (8.7)]. <BR>                     <BR>                        •To check with their physicians before receiving live virus vaccinations [see Warnings and Precautions (5.8)].<BR>                     <BR>                     <BR>                        •Who are of reproductive potential to use effective contraceptive methods during treatment and for a minimum of 12 months following the BEXXAR therapeutic regimen [see Use in Special Populations (8.7)]. <BR>                     <BR>                        •To discontinue nursing during and after the BEXXAR therapeutic regimen [see Use in Special Populations (8.3)].<BR>                     <BR>                  <BR>                  BEXXAR is a registered trademark of GlaxoSmithKline. <BR>                  LUER-LOK is a trademark of Becton, Dickinson and Company.<BR>                  GlaxoSmithKline<BR>                  Research Triangle Park, NC 27709<BR>                  U.S. Lic. 1727<BR>                  ©2012, GlaxoSmithKline. All rights reserved.<BR>                  BXX:3PI<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>